ETON Eton Pharmaceuticals Inc.

3.83
+0.2  (+6%)
Previous Close 3.63
Open 3.89
Price To Book 7.51
Market Cap 79,901,307
Shares 20,861,960
Volume 47,387
Short Ratio
Av. Daily Volume 87,889
Stock charts supplied by TradingView

NewsSee all news

  1. Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle

    -Estimated Market Opportunity of Greater than $100 Million -Alkindi Sprinkle NDA has been Assigned a September 29, 2020 Prescription Drug User Fee Act Date -Alkindi Sprinkle has been Granted Orphan Drug Designation for

  2. Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution)

    -Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation -Market for Topiramate in Oral Form is Greater than $800 million Annually DEER PARK, Ill., March 17, 2020 (GLOBE

  3. Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results

    DEER PARK, Ill., March 05, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported

  4. Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020

    DEER PARK, Ill., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it

  5. Eton Pharmaceuticals Provides Update on ET-105 Program

    DEER PARK, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today provided an

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued July 12, 2019. NDA resubmitted in December 2019.
EM-100
Allergic conjunctivitis
NDA to be filed in 2020.
DS-100
Intractable pain
Rolling NDA filing announced March 14, 2019. However, third-party has been granted five years of market exclusivity.
DS-200
Nutritional deficiencies
aNDA filed. GDUFA target action date in October 2020. Paragraph IV litigation likely to delay the product’s final approval.
DS-300
Nutritional deficiencies
FDA Approval announced October 22, 2019.
ET-202
Injectable hospital product
NDA filing due 1H 2020.
EM-103
Hypothyroidism
NDA filing to be resubmitted in 2020.
ET-203
Injectable hospital product
NDA filing due 2020.
EM-104
Neurological indication
CRL issued March 17, 2020. Additional trial required.
EM-105
Lennox-Gastaut syndrome, epilepsy
NDA filing due 3Q 2020.
ET-101
Oral solution of topiramate

Latest News

  1. Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle

    -Estimated Market Opportunity of Greater than $100 Million -Alkindi Sprinkle NDA has been Assigned a September 29, 2020 Prescription Drug User Fee Act Date -Alkindi Sprinkle has been Granted Orphan Drug Designation for

  2. Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution)

    -Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation -Market for Topiramate in Oral Form is Greater than $800 million Annually DEER PARK, Ill., March 17, 2020 (GLOBE

  3. Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results

    DEER PARK, Ill., March 05, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported

  4. Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020

    DEER PARK, Ill., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it

  5. Eton Pharmaceuticals Provides Update on ET-105 Program

    DEER PARK, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today provided an

  6. Eton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference

    DEER PARK, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that

  7. Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement

    Xellia's US-based Hospital Sales Force Will Immediately Begin Promoting Biorphen in Collaboration with EtonAgreement Significantly Expands Biorphen Commercial Footprint and Provides Access to Institutions that Prefer

  8. Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection

    ~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen is Now Available for Order Through Major Wholesalers ~ ~ Biorphen is Eton Pharmaceuticals' First

  9. Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress

    Biorphen® Expected to Launch by End of NovemberCompany to Host Conference Call and Webcast Today at 4:30 p.m. ET (3:30 p.m. CT) DEER PARK, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc

  10. Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings

    DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has

  11. Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

    DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it

  12. Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection

    ~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen Eliminates Need for Compounding, Reducing Risks for Unsafe Injection Practices, Medication Administration

  13. Eton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference

    DEER PARK, Ill., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that